OCUL Stock: Price, Earnings History and SEC Filings
Ocular Therapeutix, Inc. (OCUL) last traded at $6.97, down 4.65% on the latest session and down 9.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.35 against an analyst estimate of $-0.40, a beat of 12.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
OCUL earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $-0.35 | $-0.40 | +12.50% |
| Mar 2026 | May 5, 2026 | $-0.41 | $-0.32 | -28.12% |
| Dec 2025 | Feb 5, 2026 | $-0.29 | $-0.33 | +12.12% |
| Sep 2025 | Nov 4, 2025 | $-0.37 | $-0.39 | +5.13% |
OCUL beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How OCUL reacts to earnings
Across its last 8 earnings releases, OCUL moved 6.3% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-03 | Before open | +2.82% |
| 2026-05-05 | Before open | -0.61% |
| 2026-02-05 | Before open | +4.21% |
| 2025-11-04 | Before open | -4.47% |
| 2025-08-05 | Before open | -2.83% |
| 2025-05-05 | Before open | -12.16% |
| 2025-03-03 | Before open | -17.02% |
| 2024-11-14 | Before open | -6.42% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
OCUL financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $52M | -$266M | -$217M | -511.9% | $-1.42 |
| 2024 | $64M | -$194M | -$136M | -303.7% | $-1.22 |
| 2023 | $58M | -$81M | -$76M | -138.1% | $-1.02 |
| 2022 | $51M | -$71M | -$63M | -138.0% | $-0.97 |
| 2021 | $44M | -$7M | -$67M | -15.1% | $-0.98 |
| 2020 | $17M | -$156M | -$54M | -894.3% | $-2.56 |
| 2019 | $4M | -$86M | -$80M | -2043.3% | $-1.91 |
| 2018 | $2M | -$60M | -$51M | -3014.0% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for OCUL
- 8-K · Oct 16, 2026Officer or director change
- 10-Q · Aug 3, 2026
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 12, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 30, 2026
- 8-K · Feb 27, 2026Regulation FD disclosure
- 10-K · Feb 5, 2026
- 8-K · Feb 5, 2026Results of operations, Financial statements and exhibits
Insider filing activity
OCUL insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
OCUL news
- Ocular Therapeutix™ to Participate in November Investor and Scientific ConferencesOct 29, 2026 · finance.yahoo.com
- Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 WinOct 20, 2026 · marketbeat.com
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (OCUL) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.